Derek Archila Analyst PerformanceManaging Director, Biotechnology Equity Research at Wells Fargo & CompanyDerek Archila is a stock analyst at Wells Fargo & Company in the medical sector, covering 52 publicly traded companies. Over the past year, Derek Archila has issued 27 stock ratings, including buy and hold recommendations. While full access to Derek Archila's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Derek Archila's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings259 Last 8 YearsBuy Recommendations61.87% 159 Buy RatingsCompanies Covered52 Unique Companies Ratings Distribution257RatingsDistribution of strong buy, buy, hold, and sell ratings by Derek Archila.RatingPercentageCount Strong Buy0.4%1 ratings Buy61.5%158 ratings Hold38.1%98 ratings Sell0.0%0 ratingsOut of 257 total stock ratings issued by Derek Archila at Wells Fargo & Company, the majority (61.5%) have been Buy recommendations, followed by 38.1% Hold and 0.4% Strong Buy.Best & Worst CallsBest Call0000.0%CBAYMay 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%SELBOct 2018Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ92.3% of companies on NASDAQ48 companiesNYSE7.7% of companies on NYSE4 companiesDerek Archila, an analyst at Wells Fargo & Company, currently covers 52 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical52 companies100.0%Derek Archila of Wells Fargo & Company specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE26 companies50.0%PHARMACEUTICAL PREPARATIONS16 companies30.8%MED - DRUGS4 companies7.7%BIOTECHNOLOGY3 companies5.8%BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC1 company1.9%MED PRODUCTS1 company1.9%MED - GENERIC DRG1 company1.9% About Derek ArchilaSenior Equity Research Analyst specializing in small- and mid-cap biotechnology companies, with a primary focus on immunology & inflammation (I&I), targeted oncology, and rare diseases. I am a key contributor to the #4 ranked Wells Fargo SMID-cap biotech franchise, and was individually recognized as a “Runner-Up” in the Institutional Investor (Extel) poll for Biotechnology Small & Mid-Cap Equity Research in both 2023 and 2024, ranking among the top 5 analysts in 2024.Follow on LinkedIn Derek Archila's Ratings History at Wells Fargo & Company Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export to Excel CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsATYRaTyr Pharma9/15/2025Reiterated Rating$1.05Equal Weight$0.0000.00% ROISLNOSoleno Therapeutics8/20/2025Initiated Coverage$66.81$123.00Overweight$0.0000.00% ROICLDXCelldex Therapeutics8/20/2025Lower Price Target$21.24$38.00Overweight$0.0000.00% ROISTROSutro Biopharma8/12/2025Lower Price Target$0.77$3.00Equal Weight$0.0000.00% ROIASNDAscendis Pharma A/S8/8/2025Reiterated Rating$190.35$295.00Overweight$0.0000.00% ROIVRDNViridian Therapeutics8/7/2025Lower Price Target$16.71$26.00Equal Weight$0.0000.00% ROIARVNArvinas8/7/2025Lower Price Target$6.14$16.00Overweight$0.0000.00% ROIZNTLZentalis Pharmaceuticals8/7/2025Lower Price Target$1.43$5.00Equal Weight$0.0000.00% ROIINCYIncyte8/6/2025Upgrade$77.72$89.00Overweight$0.0000.00% ROIARGXargenex7/31/2025Boost Price Target$670.33$756.00Overweight$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. INCYIncyte7/30/2025Boost Price Target$77.88$67.00Equal Weight$0.0000.00% ROIALMSAlumis7/25/2025Initiated Coverage$4.05$17.00Overweight$0.0000.00% ROIRYTMRhythm Pharmaceuticals7/10/2025Boost Price Target$89.53$129.00Overweight$0.0000.00% ROIKYMRKymera Therapeutics6/26/2025Lower Price Target$44.98$53.00Overweight$0.0000.00% ROIATYRaTyr Pharma6/20/2025Boost Price Target$5.17$25.00Overweight$0.0000.00% ROIBPMCBlueprint Medicines6/17/2025Downgrade$128.16$129.00Hold$0.0000.00% ROIAPLSApellis Pharmaceuticals6/2/2025Boost Price Target$19.21$29.00Equal Weight$0.0000.00% ROIAPLSApellis Pharmaceuticals5/8/2025Lower Price Target$17.90$26.00Equal Weight$0.0000.00% ROIARVNArvinas5/2/2025Lower Price Target$7.78$19.00Overweight$0.0000.00% ROIINCYIncyte4/30/2025Boost Price Target$61.16$59.00Equal Weight$0.0000.00% ROINRIXNurix Therapeutics4/9/2025Lower Price Target$9.86$25.00Overweight$0.0000.00% ROIRYTMRhythm Pharmaceuticals4/7/2025Boost Price Target$54.94$91.00Overweight$0.0000.00% ROIARVNArvinas3/12/2025Set Price Target$8.51$26.00Overweight$0.0000.00% ROIARGXargenex2/28/2025Boost Price Target$619.04$741.00Overweight$0.0000.00% ROIEXELExelixis2/24/2025Downgrade$36.85$36.00Equal Weight$0.0000.00% ROIANABAnaptysBio2/13/2025Boost Price Target$19.29$51.00Overweight$0.0000.00% ROIZNTLZentalis Pharmaceuticals1/30/2025Lower Price Target$1.66$6.00Equal Weight$0.0000.00% ROI Stock Forecasts and Research Tools Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.